New Insights into AGO2 Variants in Lessel-Kreienkamp Neurodevelopmental Syndrome
Overview of AGO2 and Lessel-Kreienkamp Syndrome
Recent research has expanded understanding of Lessel-Kreienkamp syndrome (LESKRES), a neurodevelopmental disorder linked to mutations in the AGO2 gene. AGO2 encodes a key protein in the RNA-induced silencing complex (RISC), which regulates gene expression through microRNAs (miRNAs). Variants in this gene disrupt normal brain development and other bodily systems, but the full range of clinical features and molecular mechanisms has remained unclear.
Study of 45 New Cases and Integration with Previous Data
A team of researchers analyzed 45 newly identified individuals carrying 33 distinct AGO2 variants, 30 of which had not been reported before. By combining these data with 70 previously documented cases, they outlined a broader clinical spectrum of LESKRES and explored correlations between specific genetic changes and symptoms.
Common Clinical Features and Systemic Involvement
All individuals exhibited neurodevelopmental challenges of varying severity. The most frequent symptoms included delayed speech and language development (97%), intellectual disability (97%), and motor delays (93%). Additional features often seen were muscular hypotonia, autistic traits, attention deficit hyperactivity disorder (ADHD), visual impairments, and structural brain abnormalities. Beyond neurological symptoms, many patients also showed systemic manifestations such as skeletal, craniofacial, cardiac, and male urogenital anomalies, highlighting AGO2’s role beyond the nervous system.
Genetic and Molecular Findings
Variants clustered in specific AGO2 protein regions critical for RISC function, including the L1 loop, helix-7, and PIWI domain loops. Functional assays revealed that only some variants, such as p.(Arg714Trp) and p.(Asn729His), impaired RNA silencing activity. Others, like p.(Asp619Asn), disrupted interactions with GW182 protein and assembly of P-bodies, cellular structures important for RNA regulation.
Several variants (p.(Arg506Gln), p.(Glu531Gln), p.(Gly604Arg), p.(Asp619Asn)) reduced phosphorylation at the protein’s C-terminal end, suggesting problems with AGO2 recycling and turnover. Additionally, co-immunoprecipitation and sequencing of AGO2-bound miRNAs showed variant-specific changes in miRNA binding, strand selection, and generation of miRNA isoforms (isomiRs). Notably, variants near the helix-7 hinge, especially p.(Phe182del), caused extensive alterations in miRNA association and 3’-end modifications, indicating impaired anchoring within the miRNA-binding pocket.
Implications for Neurodevelopment and Disease Severity
These findings emphasize AGO2’s essential role in precise miRNA-mediated gene regulation during human neurodevelopment. Disruptions in AGO2 structure and function affect multiple interconnected processes—such as P-body association, phosphorylation-dependent turnover, and miRNA interactions—leading to dysregulated post-transcriptional gene silencing. The study also documented interfamilial and variant-specific clinical variability, including cases of gonadal mosaicism, which may influence inheritance patterns and disease severity.
Considerations for Families and Future Research
Understanding the diverse molecular effects of different AGO2 variants can help clinicians better predict clinical outcomes and tailor management strategies for affected individuals. However, the complexity of genotype-phenotype relationships and the presence of systemic features beyond neurodevelopment warrant comprehensive multidisciplinary care. Further research is needed to explore potential therapeutic approaches targeting the molecular pathways disrupted in LESKRES.
For more detailed information, see the original study published in Genome Medicine: The clinical and molecular spectrum of AGO2-associated Lessel-Kreienkamp neurodevelopmental syndrome.
